Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Sees Significant Decline in Short Interest

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEBGet Free Report) saw a significant drop in short interest in April. As of April 30th, there was short interest totalling 17,900 shares, a drop of 10.9% from the April 15th total of 20,100 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 5,600 shares, the short-interest ratio is currently 3.2 days.

Anebulo Pharmaceuticals Stock Performance

Shares of NASDAQ:ANEB traded up $0.07 on Wednesday, hitting $2.35. 14,979 shares of the company’s stock were exchanged, compared to its average volume of 5,809. Anebulo Pharmaceuticals has a 1-year low of $1.62 and a 1-year high of $4.05. The company has a market capitalization of $60.23 million, a PE ratio of -5.83 and a beta of -0.98. The firm’s 50-day moving average is $2.76 and its 200 day moving average is $2.53.

Anebulo Pharmaceuticals (NASDAQ:ANEBGet Free Report) last announced its quarterly earnings results on Tuesday, February 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). On average, analysts anticipate that Anebulo Pharmaceuticals will post -0.47 EPS for the current fiscal year.

Anebulo Pharmaceuticals Company Profile

(Get Free Report)

Anebulo Pharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction. The company's lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist, which is in a Phase II clinical trial to address the unmet medical need for a specific antidote for ACI.

Further Reading

Receive News & Ratings for Anebulo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anebulo Pharmaceuticals and related companies with's FREE daily email newsletter.